ScreenerHero
AZTArcticZymes Technologies ASA
OSL · NO · Healthcare · Biotechnology · arcticzymes.com
20.80NOK-4.15%Mkt Cap: 99.30M $P/E: 69.33

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp a…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap99.30M $
Enterprise Value69.96M $
Revenue (TTM)12.00M $
Gross Profit10.07M $
Net Income (TTM)910.29K $
Revenue/Share0.2275 USD
Last Price20.80 NOK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees50
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010014632
Valuation
P/E (Trailing)69.33
P/E (Forward)40.43
PEG—
EV/EBITDA63.72
EV/Revenue5.83
P/S8.59
P/B3.26
EPS (TTM)0.30
EPS (Forward)0.53
52W Range
18.3019% of range31.40
52W High31.40 NOK
52W Low18.30 NOK
Profitability
Gross Margin95.68%
Oper. Margin-2.15%
EBITDA Margin9.15%
Profit Margin8.65%
ROE2.88%
ROA2.70%
Growth
Revenue Growth40.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF2.41M $
CapEx (TTM)340.45K $
FCF Margin10.68%
FCF Yield1.29%
Net Debt-22.90M $
Net Debt/EBITDA-20.85
Balance Sheet
Debt/Equity0.02
Current Ratio15.83
Quick Ratio14.80
Book Value/Sh6.625 NOK
Cash/Share5.171 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.00 NOK
Upside (mean)+34.6%
Target Range28.00 NOK – 28.00 NOK
# Analysts1
Ownership
Shares Out.51.07M
Float42.19M
Insiders17.41%
Institutions14.23%
Technical
SMA 5019.75 (+5.3%)
SMA 20021.11 (-1.5%)
Beta0.56
S&P 52W Chg18.16%
Avg Vol (30d)35.53K
Avg Vol (10d)61.13K
Technical Indicators
RSI (14)65.9
MACD0.3233
MACD Signal0.1093
MACD Hist.+0.2140
BB Upper21.23 NOK
BB Middle19.91 NOK
BB Lower18.59 NOK
BB Width13.31%
ATR (14)0.8382 NOK
Vol Ratio (20d)1.90x